.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,553,818

« Back to Dashboard

Claims for Patent: 7,553,818

Title:Combination therapy for effecting weight loss and treating obesity
Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
Inventor(s): Najarian; Thomas (Los Osos, CA)
Assignee: Vivus, Inc. (Mountain View, CA)
Application Number:11/385,198
Patent Claims: 1. A method for effecting a weight loss in a subject in need thereof comprising administering to said subject continually over a significant period of time an 8 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.

2. The method of claim 1 wherein the significant period of time is from 4 weeks to 67 weeks.

3. The method of claim 1 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 50 mg.

4. The method of claim 3 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.

5. The method of claim 1 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.

6. The method of claim 1 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.

7. A method for effecting weight loss in a subject in need thereof comprising administering to said subject continuously over a significant period of time a 10 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.

8. The method of claim 7 wherein the significant period of time is from 4 weeks to 67 weeks.

9. The method of claim 7 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phenetermine alone is at least about 50 mg.

10. The method of claim 9 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.

11. The method of claim 7 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.

12. The method of claim 7 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.

13. A method for effecting weight loss in a subject in need thereof comprising administering to said subject continuously over a significant period of time a 15 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.

14. The method of claim 13 wherein the significant period of time is from 4 weeks to 67 weeks.

15. The method of claim 13 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 50 mg.

16. The method of claim 15 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.

17. The method of claim 13 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.

18. The method of claim 13 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.

19. A method for effecting weight loss in a subject in need thereof comprising administering to said subject continuously over a significant period of time a 20 mg daily dose of phentermine and in combination therewith a daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone.

20. The method of claim 19 wherein the significant period of time is from 4 weeks to 67 weeks.

21. The method of claim 19 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 50 mg.

22. The method of claim 21 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is from about 50 mg to about 400 mg.

23. The method of claim 19 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 100 mg.

24. The method of claim 19 wherein the daily amount of topiramate selected to prevent the loss of effectiveness of phentermine alone is at least about 200 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc